These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35235820)

  • 41. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    G de la Torre B; Albericio F
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals.
    Lackey L; Thompson G; Eggers S
    Ther Innov Regul Sci; 2021 Jan; 55(1):170-179. PubMed ID: 32779045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accelerated approval drug labels often lack information for clinical decision-making.
    Ballreich J; Socal M; Bennett CL; Xuan A; Trujillo A; Anderson G
    Pharmacotherapy; 2023 Apr; 43(4):300-304. PubMed ID: 36872463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
    Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
    BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.
    Polanski J; Bogocz J; Tkocz A
    Drug Discov Today; 2015 Nov; 20(11):1300-4. PubMed ID: 26160060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health Canada's use of priority review status for drugs for unmet needs.
    Rawson NS
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):391-5. PubMed ID: 26260656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms.
    Scott KA; Njardarson JT
    Top Curr Chem (Cham); 2018 Jan; 376(1):5. PubMed ID: 29356979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New drug approvals for 2021: Synthesis and clinical applications.
    Yuan S; Wang DS; Liu H; Zhang SN; Yang WG; Lv M; Zhou YX; Zhang SY; Song J; Liu HM
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114898. PubMed ID: 36370552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 59. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
    Eckert JC
    Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.